Drugs / Atezolizumab
Atezolizumab
Drug FDA approvedAntineoplastic monoclonal antibody; PD-L1 inhibitor·First approved·2016
- Registered trials
- 586
- Ongoing
- 259/ 44%
- Completed
- 185
- Indications
- 5
Approved indications
| Indication |
|---|
| Non-small cell lung cancer |
| Small cell lung cancer |
| Hepatocellular carcinoma |
| Melanoma |
| Alveolar soft part sarcoma |
Clinical trial landscape
586 registered studies reference this molecule or one of its brands. The split below shows how many are ongoing versus completed per phase.
| Phase | Total | Ongoing | Completed | Split |
|---|---|---|---|---|
| Phase 2 | 255 | 114 | 76 | |
| Phase 1 | 114 | 42 | 48 | |
| Phase 1/2 | 90 | 40 | 22 | |
| Phase 3 | 84 | 43 | 29 | |
| Unknown | 16 | 6 | 7 | |
| Phase 2/3 | 12 | 8 | 1 | |
| Early Phase 1 | 7 | 1 | 1 | |
| Phase 4 | 6 | 4 | 1 | |
| Not applicable | 2 | 1 | 0 | |
| All phases | 586 | 259 | 185 |
Ongoing Completed Balance withdrawn, terminated, or status unreported.
Study records: ClinicalTrials.gov →
Mechanism of action
Blocks PD-L1 interaction with PD-1 and CD80 receptors to lift inhibitory signaling and promote anti-tumor immune response.
Recent developments
Headlines link to the original publisher. Sources limited to a reviewed list of journals, regulators, and medical press.